Research programme: anti-cancer therapeutics - OncoRx PharmaceuticalsAlternative Names: ORX 101; ORX 102; ORX 103; Tumour-activated nanodrug programme - OncoRx
Latest Information Update: 05 Dec 2015
At a glance
- Originator Unknown
- Developer OncoRx Pharmaceuticals Inc
- Class Antineoplastics; Phenothiazines; Small molecules
- Mechanism of Action Apoptosis stimulants; Integrin alpha4beta1 modulators; P-glycoprotein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Research Cancer